Our results show that Prdm3 deficiency potentiates inflammation, promotes tumor initiation and dramatically accelerates malignant progression, which is consistent with our findings indicating that PRDM3 loss is significantly associated with poorer survival in patients with PDAC. Here, MECOM is linked to neoplasm.